Emergent Biosolutions
EBS
358 hedge funds and large institutions have $4.45B invested in Emergent Biosolutions in 2020 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 110 increasing their positions, 138 reducing their positions, and 28 closing their positions.
214% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 28
58% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $7.26M
25% more capital invested
Capital invested by funds: $3.56B → $4.45B (+$891M)
20% more funds holding
Funds holding: 299 → 358 (+59)
4.19% less ownership
Funds ownership: 85.84% → 81.65% (-4.2%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 138
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$67M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$36.9M |
| 3 |
Two Sigma Investments
New York
|
+$30M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.4M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$190M |
| 2 |
State Street
Boston,
Massachusetts
|
-$38.9M |
| 3 |
Renaissance Technologies
New York
|
-$36.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$35.7M |
| 5 |
SCM
Snyder Capital Management
San Francisco,
California
|
-$24.4M |
EBS Hedge Fund Activity: Q3 2020 in Review
358 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2020, worth a combined $4.45B — up 25% from $3.56B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new EBS positions and 28 closed out — a net gain of 60 holders — while 110 added to existing stakes and 138 trimmed.
The largest buyer was 1832 Asset Management, opening a new position worth an estimated $67M. The largest seller was BlackRock, cutting an estimated $190M.
- 358 institutional investors held Emergent Biosolutions (EBS) as of Q3 2020, up from 299 in Q2 2020.
- Funds reported $4.45B of Emergent Biosolutions stock for Q3 2020, up 25% quarter-over-quarter.
- 88 funds opened new Emergent Biosolutions positions in Q3 2020 and 28 closed out, a net change of +60 holders.
- The largest Emergent Biosolutions buyer in Q3 2020 was 1832 Asset Management, an estimated $67M added.
- The largest Emergent Biosolutions seller in Q3 2020 was BlackRock, an estimated $190M sold.
Based on aggregated 13F filings for Q3 2020.